With Vaxart, Inc. (VXRT) trading at $0.4345, the chart's structure points to a clear set of levels that should govern its next moves.On the downside, primary support is $0.3340 (strength 60/100), with secondary support at —. Overhead, first resistance is $0.4400 (26/100), then $0.5133.That frames a near-term trading band of roughly 24.4% between the first...
Ocular Therapeutix, Inc. (OCUL) gives both camps something to hold. These are the 7 bullish and...
Every position is an argument with someone on the other side. Here is what the numbers...
L.B. Foster Company (FSTR) gives both camps something to hold. These are the 3 bullish and...
Every position is an argument with someone on the other side. Here is what the numbers...
from Roth Capital issued a price target of $22.00 for LOCO on 2026-10-09 11:37:17.The adjusted price target was set to $22.00.At the time of the announcement, LOCO was trading at...
Crispin Love from Piper Sandler issued a price target of $8.00 for MITT on 2026-10-09 11:22:25.The adjusted price target was set to $8.00.At the time of the announcement, MITT was...
from Roth Capital issued a price target of $12.00 for LOCO on 2026-10-09 10:20:40.The adjusted price target was set to $12.00.At the time of the announcement, LOCO was trading at...
from Barclays issued a price target of $1.00 for EVTL on 2026-10-08 20:26:18.The adjusted price target was set to $1.00.At the time of the announcement, EVTL was trading at $0.5443.The...
from Seaport Global issued a price target of $422.00 for DAVE on 2026-10-08 13:59:09.The adjusted price target was set to $422.00.At the time of the announcement, DAVE was trading at...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
